| Dawn A Palladino, LICSW, LADC | |
|
56 Old Farm Rd, Stowe, VT 05672-4434 | |
| (802) 249-1022 | |
| Not Available |
| Full Name | Dawn A Palladino |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 14 Years |
| Location | 56 Old Farm Rd, Stowe, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831609494 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 089.0127978 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valera Medical Pa | 6406238310 | 5 |
News Archive
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
A wide income gap between the most affluent and the worst off in society is closely associated with higher death rates worldwide, especially for younger adults, finds a study published on bmj.com today as part of a global theme issue on poverty and human development.
› Verified 9 days ago
| Entity Name | Clara Martin Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386710861 PECOS PAC ID: 1951395367 Enrollment ID: O20060315000608 |
News Archive
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
A wide income gap between the most affluent and the worst off in society is closely associated with higher death rates worldwide, especially for younger adults, finds a study published on bmj.com today as part of a global theme issue on poverty and human development.
› Verified 9 days ago
| Entity Name | Valera Medical Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871248757 PECOS PAC ID: 6406238310 Enrollment ID: O20220809000354 |
News Archive
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
A wide income gap between the most affluent and the worst off in society is closely associated with higher death rates worldwide, especially for younger adults, finds a study published on bmj.com today as part of a global theme issue on poverty and human development.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dawn A Palladino, LICSW, LADC Po Box 99, Morrisville, VT 05661-0099 Ph: () - | Dawn A Palladino, LICSW, LADC 56 Old Farm Rd, Stowe, VT 05672-4434 Ph: (802) 249-1022 |
News Archive
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced a major expansion of the company's U.S. biologics offering with the launch of its VESUVIUS™ Osteobiologic Systems and new additions to its VIKOS® Allograft Systems. K2M is working with LifeNet Health®, a leading allograft bio-implant and regenerative medicine company, to bring to market quality implants to enhance bone regeneration and osteoconductivity.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
A wide income gap between the most affluent and the worst off in society is closely associated with higher death rates worldwide, especially for younger adults, finds a study published on bmj.com today as part of a global theme issue on poverty and human development.
› Verified 9 days ago
Sean Ryan, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 56 Old Farm Rd, Stowe, VT 05672 Phone: 802-433-4134 | |
Holly D Ryan, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 56 Old Farm Rd, Stowe, VT 05672 Phone: 802-760-7497 | |
Luke Smith, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 515 Moscow Rd, Stowe, VT 05672 Phone: 802-696-8900 |